Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure

Table 4

Echocardiography-derived measurements of myocardial performance and BNP blood levels (mean ± SD) in SSc patients with normal or elevated PASP.

	RV Tei-index	LV Tei-index	LV EF (%)	BNP (pg/mL)
PASP ≤40 mm Hg (all patients, 𝑛 = 69)	0.37±0.02	0.38±0.01	61 ± 9	33 ± 23
PASP >40 mm Hg (all patients, 𝑛 = 37)	0.41±0.03(𝑃<.001)^∗	0.41±0.02(𝑃<.001)^∗	60 ± 5	163 ± 159 (𝑃<.0001)^∗
PASP >40 mm Hg (diffuse SSc, 𝑛 = 21)	0.41±0.03	0.41±0.02	60 ± 5	167 ± 187
PASP >40 mm Hg (limited SSc, 𝑛 = 16)	0.42±0.03	0.40±0.02	61 ± 4	164 ± 120

SSc: systemic sclerosis;  PASP: pulmonary artery systolic pressure;  BNP: B-type natriuretic peptide;  RV: right ventricular;  LV: left ventricular;  EF: ejection fraction.^*Comparing to patients with PASP ≤40.